In a report released yesterday, Stephanie Davis from Barclays reiterated a Buy rating on GoodRx Holdings (GDRX – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $6.54.
Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Laboratory, and McKesson. According to TipRanks, Davis has an average return of -6.7% and a 43.16% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GoodRx Holdings with a $7.39 average price target, implying a 13.00% upside from current levels. In a report released on February 12, Citi also maintained a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $9.37 and a one-year low of $4.14. Currently, GoodRx Holdings has an average volume of 1.56M.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GDRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GoodRx Holdings (GDRX) Company Description:
GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.
Read More on GDRX:
- GoodRx Holdings Enhances Financial Stability and Restructures Leadership
- J&J lawsuit may spur adoption of GoodRx program, says Citi
- GoodRx price target raised to $6.50 from $6 at Goldman Sachs
- GoodRx to eliminate role currently held by Chief Operating Officer Raj Beri
- GoodRx price target raised to $7 from $5 at RBC Capital
